Home » Posts tagged with » Richard Pazdur
Celgene bags Inrebic FDA approval for myelofibrosis

Celgene bags Inrebic FDA approval for myelofibrosis

Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

Continue reading …
Ablynx wins Cablivi FDA approval for rare blood clotting disorder

Cablivi FDA approval : Belgian biopharma company Ablynx has bagged approval from the US Food and Drug Administration (FDA) for its anti-vWF nanobody Cablivi (caplacizumab-yhdp) injection in combination with plasma exchange and immunosuppressive therapy for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). According to the FDA, aTTP is a rare blood clotting disorder in […]

Continue reading …
Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma

Adcetris FDA approval : Seattle Genetics has secured new approval from the US Food and Drug Administration (FDA) for its monoclonal antibody Adcetris (brentuximab vedotin), which is in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for the treatment of certain types of peripheral T-cell lymphoma (PTCL). Adcetris FDA approval for PTCL in combination with CHP […]

Continue reading …
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia treatment

Lumoxiti FDA approval : AstraZeneca has bagged the US Food and Drug Administration (FDA) approval for its CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of relapsed or refractory hairy cell leukaemia (HCL). Lumoxiti FDA approval for hairy cell leukaemia treatment is for adult patients who had undergone more than two systemic therapies in the […]

Continue reading …
FDA approves Agios’ Tibsovo for acute myeloid leukemia treatment

Tibsovo (ivosidenib) developed by Agios Pharmaceuticals has been approved by the US Food and Drug Administration (FDA) for acute myeloid leukemia treatment in patients with a specific genetic mutation and whose condition relapsed or is refractory. The Agios AML drug has been indicated to be used with an FDA-approved companion diagnostic that will detect specific […]

Continue reading …